Year All20232022202120202019 Aug 22, 2022 Verve Therapeutics Highlights Preclinical Data Supporting Nomination of VERVE-201 ANGPTL3 Product Candidate at the European Society of Cardiology 2022 Congress Aug 09, 2022 Verve Therapeutics Provides Corporate Updates and Reports Second Quarter 2022 Financial Results Jul 25, 2022 Verve Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares Jul 21, 2022 Verve Therapeutics Announces Pricing of Upsized Public Offering of Common Stock Jul 20, 2022 Verve Therapeutics Announces Proposed Public Offering of Common Stock Jul 20, 2022 Vertex and Verve Therapeutics Establish Collaboration to Discover and Develop an In Vivo Gene Editing Program for Liver Disease Jul 12, 2022 Verve Therapeutics Doses First Human with an Investigational In Vivo Base Editing Medicine, VERVE-101, as a Potential Treatment for Heterozygous Familial Hypercholesterolemia Jun 13, 2022 Verve Therapeutics Appoints Experienced Biotechnology Executive, Alexander G. “Bo” Cumbo, to its Board of Directors Jun 01, 2022 Verve Therapeutics to Participate in the 2022 Jefferies Healthcare Conference May 10, 2022 Verve Therapeutics Announces Clearance of First VERVE-101 Clinical Trial Application and Outlines Global Clinical Development Strategy; Reports First Quarter 2022 Financial Results
Aug 22, 2022 Verve Therapeutics Highlights Preclinical Data Supporting Nomination of VERVE-201 ANGPTL3 Product Candidate at the European Society of Cardiology 2022 Congress
Aug 09, 2022 Verve Therapeutics Provides Corporate Updates and Reports Second Quarter 2022 Financial Results
Jul 25, 2022 Verve Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
Jul 20, 2022 Vertex and Verve Therapeutics Establish Collaboration to Discover and Develop an In Vivo Gene Editing Program for Liver Disease
Jul 12, 2022 Verve Therapeutics Doses First Human with an Investigational In Vivo Base Editing Medicine, VERVE-101, as a Potential Treatment for Heterozygous Familial Hypercholesterolemia
Jun 13, 2022 Verve Therapeutics Appoints Experienced Biotechnology Executive, Alexander G. “Bo” Cumbo, to its Board of Directors
May 10, 2022 Verve Therapeutics Announces Clearance of First VERVE-101 Clinical Trial Application and Outlines Global Clinical Development Strategy; Reports First Quarter 2022 Financial Results
